GlassScriptPhysician profile
Charles B Davis
NPI 1891711628
$4,465.17
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $641 · 2021: $953 · 2022: $869 · 2023: $851 · 2024: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $567.29 | 2021-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $455.12 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $433.03 | 2019-2024 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $427.39 | 2020-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $370.62 | 2019-2024 | Trintellix |
| Lundbeck LLC | $293.64 | 2019-2024 | Rexulti |
| Alkermes, INC. | $240.08 | 2019-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $223.13 | 2019-2023 | Ingrezza |
| Tris Pharma INC | $206.98 | 2020-2023 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $195.59 | 2019-2024 | Uzedy, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $144.05 | 2020-2022 | |
| Neos Therapeutics, LP | $117.64 | 2019-2022 | |
| Corium, LLC | $113.06 | 2021-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $89.87 | 2022-2023 | Qelbree |
| Allergan, INC. | $82.41 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $77.35 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Axsome Therapeutics, INC. | $67.85 | 2023-2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $63.74 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $56.51 | 2019-2022 | |
| Indivior INC. | $49.93 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $43.83 | 2020-2021 | |
| Eisai INC. | $34.50 | 2020-2021 | |
| Adlon Therapeutics L.P. | $30.02 | 2019-2020 | |
| Noven Therapeutics, LLC | $29.96 | 2023-2024 | Xelstrym |
| Shire North American Group INC | $29.37 | 2019 | |
| Bioxcel Therapeutics, INC. | $22.21 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.